VeriStrat predicts patient outcomes in cancer therapy; U.K. NHS could use Down syndrome blood test by 2017;

> Biodesix's VeriStrat biomarker test picked those patients most likely to have better outcomes when treated with gemcitabine or erlotinib. Press release

> U.K. NHS could be using a blood test for Down syndrome screening by 2017, avoiding up to 300 miscarriages a year. Article

> A mutation in a gene that metabolizes amino acids acts as a marker for autism and epilepsy that may be treatable through diet. Press release | Abstract | Article | Article

> SOX2 mutations can be linked with aggressive lung cancer Abstract | Press release

> Changes in methylation patterns on DNA tag prostate cancer. Press release | Abstract

> Around half of people have thyroid nodules, but most of these are harmless; an 8-gene assay could pick out those that are cancerous, avoiding unnecessary surgery. Press release | Paper

> Inform Genomics has completed enrollment for the first phase of development for its lead platform product OnPART. Press release

And Finally… Eco-friendly blood glucose monitor could make diabetes checking greener. Article

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.